AveXis gets FDA nod to start pivotal gene therapy trial – BioPharma Dive
Barron’s |
AveXis gets FDA nod to start pivotal gene therapy trial
BioPharma Dive The infants will be given a once-only dose of the gene therapy AVXS-101, based on one of the doses from the previous Phase 1 trial. The study could readout in 2019. AveXis anticipates starting its study in patients with SMA type 2 in the fourth quarter … AveXis, Inc. (AVXS) – Citigroup Maintains Rating And Updates Price Target |
